207940.KS vs DVA — which is stronger right now?
Same dated snapshot (2026-09-01): 207940.KS quality —/100 vs DVA 100/100; engine LONG vs LONG. The comparison below is computed, dated, and auditable — not an opinion.
| Snapshot | 2026-09-01 · source: yahoo | |
|---|---|---|
| 207940.KS (Samsung Biologics) | DVA (DaVita) | |
| Market / sector | kr · Biotech | us · Healthcare |
| Price | ₩1,587,000 | $178.88 |
| Quality score | —/100 | 100/100 |
| Engine signal | LONG · 23 bars · uPnL +4.5% | LONG · 142 bars · uPnL +32.8% |
| Total return | -8.5% | +23.4% |
Thesis-break template (Biotech)
top-customer revenue contracting two straight quarters; sustained gross-margin compression; a rival commoditizing the core product; debt-funded buybacks
Cite this page
Balance Labs Research Desk (2026-09-01). "207940.KS vs DVA — which is stronger right now?." balancelabs.app · https://balancelabs.app/stocks/compare/207940.ks-vs-dva · CC BY 4.0
Ask anything
30 free credits monthly · no card required · research support, not advice
← compare hub · snapshot 2026-09-01 · not investment advice